L.J. Altfest & Co’s Moderna MRNA Stock Holding History

L.J. Altfest & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,897	Closed	-$225K	–	355
2024 Q2	$225K	Buy	+1,897	New	+$240K	0.03%	290

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

L.J. Altfest & Co's MRNA Position: Q3 2024 in Review

L.J. Altfest & Co sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,897 shares — an estimated $225K sold.

L.J. Altfest & Co first reported a position in MRNA in Q2 2024 and held it in 1 quarter. The position peaked at $225K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

L.J. Altfest & Co reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
L.J. Altfest & Co sold 1,897 Moderna shares in Q3 2024, an estimated $225K.
L.J. Altfest & Co first reported a position in Moderna in Q2 2024 and held it in 1 quarter.
L.J. Altfest & Co's Moderna position peaked at $225K in Q2 2024.
788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on L.J. Altfest & Co's 13F filing for Q3 2024, filed 5 Nov 2024.